Non-steroidal anti-inflammatory drugs and apoptosis in the gastrointestinal tract: Potential role of the pentose phosphate pathways

European Journal of Pharmacology

Volumn 397, Issue 1, 2000, Pages 1-9

  Porter, Shane N ^a,b,c,d   Howarth, Gordon S ^c,d   Butler, Ross N ^a,b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^c CHILD HEALTH RESEARCH INSTITUTE   (Australia)

^d Div of Hlth Sciences and Nutrition   (Australia)

Author keywords

Apoptosis; Colon cancer; Non steroidal anti inflammatory drug (NSAID); Pentose phosphate pathway; Ulcer

Indexed keywords

ACETYLSALICYLIC ACID; CASPASE; CELECOXIB; DICLOFENAC; ENDONUCLEASE; IBUPROFEN; INDOMETACIN; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PROSTAGLANDIN SYNTHASE; SULINDAC;

APOPTOSIS; ARTHRITIS; CELL PROLIFERATION; COLON CANCER; DIGESTIVE SYSTEM CANCER; ENERGY METABOLISM; ENZYME INHIBITION; GASTRODUODENAL ULCER; GLUCOSE METABOLISM; GLYCOLYSIS; HUMAN; HUMAN CELL; INFLAMMATION; OXIDATION REDUCTION STATE; OXIDATIVE PHOSPHORYLATION; PENTOSE PHOSPHATE CYCLE; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; DIGESTIVE SYSTEM; HUMANS; PENTOSE PHOSPHATE PATHWAY;

EID: 0034717224     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(00)00237-5     Document Type: Review

References (68)

1. Adams S.S., Cobb R. A possible basis for the anti-inflammatory activity of salicylates and other non-hormonal anti-rheumatic drugs. Nature. 4611:1958;773-774.
2. Arends M.J., Wyllie A.H. Apoptosis: mechanisms and roles in pathology. Int. Rev. Exp. Pathol. 32:1991;223-254.
3. Baker S.J., Fearon E.R., Nigro J.M., Hamilton S.R., Preisinger A.C., Jessup J.M., van Tuinen P., Ledbetter D.H., Barker D.F., Nakamura Y., White R., Vogelstein B. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science. 244:1989;217-221.
4. Banki K., Hutter E., Colombo E., Gonchoroff N.J., Perl A. Glutathione levels and sensitivity to apoptosis are regulated by changes in transaldolase expression. J. Biol. Chem. 271:1996;32994-33001.
5. Boise L.H., Gonzàlez-Garcia M., Postema C.E., Ding L., Lindsten T., Turka L.A., Mao X., Nuñez G., Thompson C.B. Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell. 74:1993;597-608.
6. Boros L.G., Puigjaner J., Cascante M., Lee W.-N.P., Brandes J.L., Bassilian S., Yusuf F.I., Williams R.D., Muscarella P., Melvin W.S., Schirmer W.J. Oxythiamine and dehydroepiandrosterone inhibit the nonoxidative synthesis of ribose and tumour cell proliferation. Cancer Res. 57:1997;4242-4248.
7. Bus P.J., Nagtegaal I.D., Verpsaget H.W., Lamers C.B.H.W., Geldof H., van Krieken J.H.J.M., Griffoien G. Mesalazine-induced apoptosis of colorectal cancer: on the verge of a new chemopreventive era? Aliment. Pharmacol. Ther. 13:1999;1397-1402.
8. Butler R.N., Arora K.K., Collins J.G., Flanigan I., Lawson M.J., Roberts-Thomson I.C., Williams J.F. Pentose phosphate pathway in rat colonic epithelium. Biochem. Int. 22:1990;249-260.
9. Butler R.N., Butler W.J., Antoniou D., Pascoe V. Effect of dehydroepiandrosterone on pentose phosphate pathway activity in the rat colon. Int. J. Biochem. 25:1993;1601-1607.
10. Castaño E., Dalmau M., Barragán M., Bartrons R., Gils J. Aspirin induces cells death and caspase-dependent phosphatidylserine externalization in HT-29 human colon adenocarcinoma cells. Br. J. Cancer. 81:1999;294-299.
11. Dang C.V., Lewis B.C., Dolde C., Dang G., Shim H. Oncogenes in tumor metabolism, tumorigenesis and apoptosis. J. Bioenerg. Biomembr. 29:1997;345-354.
12. Elder D.J.E., Hague A., Hicks D.J., Paraskeva C. Differential growth inhibition by the aspirin metabolite salicylate in human colorectal tumor cell lines: enhanced apoptosis in carcinoma and in vitro-transformed adenoma relative to adenoma cell lines. Cancer Res. 56:1996;2273-2276.
13. Enari M., Sakahira H., Yokoyama H., Okawa K., Iwamatsu A., Nagata S. A caspase-activated Dnase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature. 391:1998;43-50.
14. Evan G., Littlewood T. The role of c-myc in cell growth. Curr. Opin. Genet. Dev. 3:1993;44-49.
15. Evan G.I., Wyllie A.H., Gilbert C.S., Littlewood T.D., Land H., Brooks M., Waters C.M., Penn L.Z., Hancock D.C. Induction of apoptosis in fibroblasts by c-myc protein. Cell. 63:1992;119-128.
16. Farrow S.N., White J.H.M., Martinou I., Raven T., Pun K.T., Grinham C.J., Martinou J.C., Brown R. Cloning of a bcl-2 homologue by interaction with adenovirus E1B 19K. Nature. 374:1995;731-733.
17. Fosslien E. Adverse effects of nonsteroidal anti-inflammatory drugs on the gastrointestinal system. Ann. Clin. Lab. Sci. 28:1998;67-81.
18. Guyton A.C. General principles of gastrointestinal function - motility, nervous control and blood circulation. Textbook of Medical Physiology. 8th edn. 1994;688-697 Saunders, Philadelphia, PA.
19. Han P.F., Han G.Y., McBay H.C., Johnson J. Jr. Inactivation of yeast glucose-6-phosphate dehydrogenase by aspirin. Experientia. 36:1980;1149-1150.
20. Hanif R., Pittas A., Feng Y., Koutsos M.I., Qiao L., Staiano-Caico L., Shiff S.I., Rigas B. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer by a prostaglandin-independent pathway. Biochem. Pharmacol. 52:1996;237-245.
21. Hetts S.W. To die or not to die: an overview of apoptosis and its role in disease. JAMA. 279:1998;300-307.
22. Kamada S., Shimono A., Shito Y., Tsujimura T., Takahashi T., Noda T., Kitamura Y., Kondoh H., Tsujimoto Y. Bcl-2 deficiency in mice leads to pleiotropic abnormalities: accelerated lymphoid cell death in thymus and spleen, polycystic kidney, hair hypopigmentation and distorted small intestine. Cancer Res. 55:1995;354-359.
23. Kemmelmeier F.S., Bracht A. Effects of the nonsteroidal anti-inflammatory drug mefenamic acid on energy metabolism in the perfused rat liver. Biochem. Pharmacol. 38:1989;823-830.
24. Krajewska M., Wang H.G., Krajewski S., Zapata J.M., Shabaik A., Gascoyne R., Reed J.C. Immunohistochemical analysis of in vivo patterns of expression of CPP32 (caspase-3), a cell death protease. Cancer Res. 57:1997;1605-1613.
25. Krajewski S., Krajewska M., Shabaik A., Miyashita T., Wang H.G., Reed J.C. Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of bcl-2. Am. J. Pathol. 115:1994;1323-1336.
26. Kusuhara H., Matsuyuki H., Matsuura M., Imayoshi T., Okumoto T., Matsui H. Induction of apoptotic DNA fragmentation by nonsteroidal anti-inflammatory drugs in cultured rat gastric mucosal cells. Eur. J. Pharmacol. 360:1998;273-280.
27. Langman M.J.S. Epidemiologic evidence on the association between peptic ulceration and antiinflammatory drug use. Gastroenterology. 96:1989;640-646.
28. Larkai E.N., Smith J.L., Lidsky M.D., Graham D.Y. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic non-steroidal anti-inflammatory drug use. Am. J. Gastroenterol. 82:1987;1153-1158.
29. Laurence D.R., Bennett P.N. Inflammation and non-steroidal anti-inflammatory drugs: arthritis. Clinical Pharmacology. 6th edn. 1987;279-290 Churchill Livingstone, Edinburgh, UK.
30. Lin D., Shields M.T., Ullrich S.J., Apella E., Mercer W.E. Growth arrest induced by wild-type p53 protein blocks cells prior to or near the restriction point in late G1 phase. Proc. Natl. Acad. Sci. U. S. A. 89:1992;9210-9214.
31. Lincz L.F. Deciphering the apoptotic pathway: all roads lead to death. Immunol. Cell Biol. 76:1998;1-19.
32. Mahmud T., Rafi S.S., Scott D.L., Wrigglesworth J.M., Bjarnason I. Nonsteroidal anti-inflammatory drugs and uncoupling of oxidative phosphorylation. Arthritis Rheum. 39:1996;1998-2003.
33. Martini G., Ursini M.V. A new lease of life for an old enzyme. BioEssays. 18:1996;631-637.
34. Mitchell J.A., Warner T.D. COX-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy. Br. J. Pharmacol. 128:1999;1121-1132.
35. Moreno-Sánchez R., Bravo C., Vásquez C., Ayala G., Silviera L.H., Martínez-Lavín M. Inhibition and uncoupling of oxidative phsophorylation by non-steroidal anti-inflammatory drugs: study in mitochondria, submitochondrial particles, cells and whole heart. Biochem. Pharmacol. 57:1999;743-752.
36. Palmer A.M. The activity of the pentose phosphate pathway is increased in response to oxidative stress in Alzheimer's disease. J. Neural Transm. 106:1999;317-328.
37. Pandolfi P.P., Sonati F., Rivi R., Mason P., Grosveld F., Luzzatto L. Targeted disruption of the housekeeping gene encoding glucose-6-phosphate dehydrogenase (G6PD): G6PD is dispensable for pentose synthesis but essential for defence against oxidative stress. EMBO J. 14:1995;5209-5215.
38. Petrescu I., Tarba C. Uncoupling effects of diclofenac and aspirin in the perfused liver and isolated hepatic mitochondria of rat. Biochim. Biophys. Acta. 1318:1997;385-394.
39. Piazza G.A., Rahm A.K., Finn T.S., Fryer B.H., Stoumen A.L., Pamakcu R., Ahnen D.J. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of COX inhibition, cell cycle arrest, and p53 induction. Cancer Res. 57:1997;2452-2459.
40. Piotrowski J., Slomiany A., Slomiany B.L. Activation of apoptotic caspase-3 and nitric oxide synthase-2 in gastric mucosal injury induced by indomethacin. Scand. J. Gastroenterol. 2:1999;129-134.
41. Pritchard D.M., Watson A.J.M. Apoptosis and gastrointestinal pharmacology. Pharmacol. Ther. 72:1996;149-169.
42. Qiao L., Hanif R., Sphicas E., Shiff S.J., Rigas B. Effect of aspirin on induction of apoptosis in HT-29 human colon adenocarcinoma cells. Biochem. Pharm. 55:1998;53-64.
43. Rang H.P., Dale M.M. Drugs used to suppress inflammatory and immune reactions. Pharmacology. 2nd edn. 1991;281-305 Churchill Livingstone, Edinburgh, UK.
44. Sakahira H., Enari M., Nagata S. Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis. Nature. 391:1998;96-99.
45. Sengupta T., Datta C., Dasgupta J., De K., Saha U., Sengupta D. In vitro effect of aspirin on NADPH producing pathway in developing human fetus. Ind. J. Exp. Biol. 25:1987;202-203.
46. Schachna L., Ryan P.F.J. COX-2 inhibitors: the next generation of non-steroidal anti-inflammatory drugs. Med. J. Aust. 171:1999;175-176.
47. Simon L.S., Weaver A.L., Graham D.Y., Kivitz A.J., Lipsky P.E., Hubbard R.C., Isakson P.C., Verburg K.M., Yu S.S., Zhao W.W., Geis G.S. Anti-inflammatory and uppegastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. J. Am. Med. Assoc. 282:1999;1921-1928.
48. Smalley W., Ray W.A., Daugherty J., Griffin M.R. Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer. Arch. Intern. Med. 159:1999;161-166.
49. Somasundaram S., Rafi S., Hayllar J., Sigthorsson G., Jacob M., Price A.B., Macpherson A., Mahomd T., Scott D., Wrigglesworth J.M., Bjarnason I. Mitochondrial damage: a possible mechanism of the ìtopicalî phase of NSAID induced injury to the rat intestine. Gut. 41:1997;344-353.
50. Spangler R.S. COX 1 and 2 in rheumatic disease: implications for nonsteroidal anti-inflammatory drug therapy. Semin. Arthritis Rheum. 26:1996;435-446.
51. Stennicke H.R., Salvesen G.S. Properties of the caspases. Biochim. Biophys. Acta. 1387:1998;17-31.
52. Stockman J.A. III, Lubin B., Oski F.A. Aspirin-induced hemolysis: the role of concomitant oxidant (H2O2) challenge. Pediatr. Res. 12:1978;927-931.
53. Stryer L. Pentose phosphate pathway and gluconeogenesis. Biochemistry. 3rd edn. 1988;427-448 Freeman, New York, NY.
54. Subbaramaiah K., Zakim D., Weksler B.B., Dannenberg A.J. Inhibition of COX: a novel approach to cancer prevention. Proc. Soc. Exp. Biol. Med. 216:1997;201-210.
55. Thompson E.B. The many roles of c-Myc in apoptosis. Annu. Rev. Physiol. 60:1998;575-600.
56. Thun M.J. Aspirin and gastrointestinal cancer. Adv. Exp. Med. Biol. 400A:1997;395-402.
57. Tian W.N., Braunstein L.D., Pang J. Importance of glucose-6-phosphate dehydrogenase activity for cell growth. J. Biol. Chem. 273:1998;10609-10617.
58. Tian W.N., Braunstein L.D., Apse K., Pang J., Rose M., Tian X., Stanton R.C. Importance of glucose-6-phosphate dehydrogenase in cell death. Am. J. Physiol. 276:1999;C1121-C1131.
59. Vane J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol. 231:1971;232-235.
60. Villa P., Kaufmann S.H., Earnshaw W.C. Caspases and caspase inhibitors. Trends Biochem. Sci. 22:1997;388-393.
61. Walker P.R., Sikorska M. New aspects of the mechanism of DNA fragmentation in apoptosis. Biochem. Cell Biol. 75:1997;287-299.
62. Wallace J.L., Tigley A.W. New insights into prostaglandins and mucosal defence. Aliment. Pharmacol. Ther. 9:1995;227-235.
63. Wallace J.L., Bak A., McKnight W., Asfaha S., Sharkey K.A., MacNaughton W.K. COX 1 contributes to inflammatory responses in rats and mice: implications for gastrointestinal toxicity. Gastroenterology. 115:1998;101-109.
64. Watson A.J.M. Review article: manipulation of cell death - the development of novel strategies for the treatment of gastrointestinal disease. Aliment. Pharmacol. Ther. 9:1995;215-226.
65. Whitehouse M.W. Biochemical properties of anti-inflammatory drugs. III. Uncoupling of oxidative phosphorylation in a connective tissue (cartilage) or liver mitochondria by salicylate analogues: relationship of structure to function. Biochem. Pharmacol. 13:1964;319-336.
66. Yang E., Zha J., Boise L.H., Thompson C.B., Korsmeyer S.J. Bad, a heterodimeric partner for bcl-xL and Bcl-2, displaces Bax and promotes cell death. Cell. 80:1995;285-291.
67. Zhu G.H., Wong B.C.Y., Ching C.K., Lai K.C., Lam S.K. Differential apoptosis by indomethacin in gastric epithelial cells through consitutive expression of wild-type p53 and/or up-regulation of c-myc. Biochem. Pharmacol. 58:1999;193-200.
68. Zunino F., Perego P., Pilotti S., Pratesi G., Supino R., Arcamone F. Role of apoptotic response in cellular resistance to cytotoxic agents. Pharmacol. Ther. 76:1997;177-185.